Home › NDC Lookup › RxCUI directory › RxCUI 1495070

Miltefosine 50 MG Oral Capsule [Impavido] — RxCUI 1495070

RxNorm drug concept · Semantic branded drug
RxCUI 1495070 Semantic branded drug · SBD ● Current RxNorm concept 1 FDA product 1 package NDC Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI1495070
Official nameMiltefosine 50 MG Oral Capsule [Impavido]
Concept typeSemantic branded drug (SBD)
RxNorm statusCurrent RxNorm concept
Also known asImpavido 50 MG Oral Capsule
FDA products mapped1
Package NDCs mapped1
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

🕸️ Concept Web — How Miltefosine 50 MG Oral Capsule [Impavido] Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Miltefosine 50 MG Oral Capsule [Impavido] RxCUI 1495070

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 1

    The active substance itself — no strength, form, or brand attached yet.

    • Miltefosine 1494066
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Impavido 1495065
  3. Dose forms 9

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Miltefosine Oral Capsule 1494070
    • Miltefosine Oral Product 1494068
    • Miltefosine Pill 1494069
    • Miltefosine Oral Capsule [Impavido] 1495067
    • Impavido Oral Product 1495068
    • Impavido Pill 1495069
    • Oral Capsule 316965
    • Oral Product 1151131
    • +1 more in this family
  4. Clinical & branded drugs 3

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 13 of 14 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Miltefosine 50 MG Oral Capsule SCD · 1494071
  • Miltefosine 50 MG SCDC · 1494067
  • Miltefosine Oral Capsule SCDF · 1494070
  • Miltefosine Oral Product SCDG · 1494068
  • Miltefosine Pill SCDG · 1494069

Brand-Name Concepts

  • Miltefosine 50 MG [Impavido] SBDC · 1495066
  • Miltefosine Oral Capsule [Impavido] SBDF · 1495067
  • Impavido Oral Product SBDG · 1495068
  • Impavido Pill SBDG · 1495069
  • Impavido BN · 1495065

📦 FDA Products & Package NDCs

1 product · 1 package NDC
1 package NDC map to RxCUI 1495070 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
69051-0300-01 2 BLISTER PACK in 1 CARTON (69051-300-01) / 14 CAPSULE in 1... IMPAVIDO Profounda, Inc. 2015-10-29
Observed labelers: Profounda, Inc. (1) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.